Telcagepant

DB12228InvestigationalSmall molecule

Telcagepant has been investigated for the treatment of Migraine. It is an antagonist of the receptor for calcitonin gene-related peptide (CGRP), a primary neuropeptide involved in the pathophysiology of migraine.... CGRP and its receptors are found in areas of the central and peripheral nervous system that are important for the transmission of migraine pain.

Mechanism: Telcagepant blocks the binding of CGRP to receptors within the areas of the central and peripheral nervous system that are important for the transmission of migraine pain and thereby is believed to inhibit the transmission of pain signals that lead to migraine headaches.
Curator reviewed
Formula / weight: C₂₆H₂₇F₅N₆O₃ · 566.523 g/mol (avg)
Code names: MK-0974

Resolves to

Compound

UNIID42O649ALLCAS781649-09-0ChEMBLCHEMBL236593PubChem11319053

Structure

InChIKeyCGDZXLJGHVKVIE-DNVCBOLYSA-NSMILESFC1=C(F)C(=CC=C1)[C@@H]1CC[C@@H](NC(=O)N2CCC(CC2)N2C(=O)NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1

Targets

Q16602CALCRLP06881CALCAP10092CALCB

What you can answer from here — as of August 30, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Telcagepant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account